Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis

Background/Aims: High‐fat dietary intake and low physical activity lead to insulin resistance, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Recent studies have shown an effect of glucagon‐like peptide‐1 (GLP‐1) on hepatic glucose metabolism, although GLP‐1 receptors (GLP‐1r) have not been found in human livers. The aim of this study was to investigate the presence of hepatic GLP‐1r and the effect of exenatide, a GLP‐1 analogue, on hepatic signalling.

[1]  A. Barnett,et al.  The Incretin System , 2013 .

[2]  D. Drucker,et al.  Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. , 2010, Endocrinology.

[3]  F. Anania,et al.  Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway , 2010, Hepatology.

[4]  B. Fielding,et al.  Liver fat and lipid oxidation in humans , 2009, Liver international (Print).

[5]  L. J. Hardies,et al.  Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis , 2009, Hepatology.

[6]  D. Andersen,et al.  Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. , 2009, The Journal of clinical endocrinology and metabolism.

[7]  K. Cusi.  Nonalcoholic fatty liver disease in type 2 diabetes mellitus , 2009, Current opinion in endocrinology, diabetes, and obesity.

[8]  D. Drucker,et al.  The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. , 2009, Endocrinology.

[9]  J. Holst,et al.  Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion , 2009, Diabetologia.

[10]  R. Bergman,et al.  Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver , 2009, Diabetes.

[11]  J. Holst,et al.  The incretin system and its role in type 2 diabetes mellitus , 2009, Molecular and Cellular Endocrinology.

[12]  K. Cusi,et al.  New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) , 2009, Annals of medicine.

[13]  G. Tell,et al.  Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. , 2008, Trends in molecular medicine.

[14]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[15]  S. Woods,et al.  Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. , 2007, Endocrinology.

[16]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[17]  S. Glaser,et al.  Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. , 2007, Gastroenterology.

[18]  C. Caelles,et al.  Hypoglycemic Action of Thiazolidinediones/Peroxisome Proliferator–Activated Receptor γ by Inhibition of the c-Jun NH2-Terminal Kinase Pathway , 2007, Diabetes.

[19]  E. Hahm,et al.  Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis , 2007, Diabetes.

[20]  J. Reubi,et al.  GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting , 2007, Journal of Nuclear Medicine.

[21]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[22]  G. Svegliati-Baroni,et al.  A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. , 2006, The American journal of pathology.

[23]  F. Anania,et al.  Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.

[24]  Robert A Hegele,et al.  Retinoid X receptor heterodimers in the metabolic syndrome. , 2005, The New England journal of medicine.

[25]  G. Marchesini,et al.  Insulin resistance: A metabolic pathway to chronic liver disease , 2005, Hepatology.

[26]  D. Dardevet,et al.  Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[27]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[28]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[29]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[30]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[31]  G. Tsujimoto,et al.  Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 , 2005, Nature Medicine.

[32]  D. D’Alessio,et al.  Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[33]  J. Clore,et al.  Dietary n‐3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats , 2004, Hepatology.

[34]  T. Warner,et al.  PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  Michael Karin,et al.  A central role for JNK in obesity and insulin resistance , 2002, Nature.

[36]  American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[37]  J. Holst.  Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1? , 2002, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[38]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[39]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[40]  S. Biswal,et al.  Inhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886 , 2001 .

[41]  N. Barzilai,et al.  Surgical removal of visceral fat reverses hepatic insulin resistance. , 1999, Diabetes.

[42]  F. Ridolfi,et al.  Fibrogenic effect of oxidative stress on rat hepatic stellate cells , 1998, Hepatology.

[43]  V. Marks,et al.  Attenuated GLP-1 secretion in obesity: cause or consequence? , 1996, Gut.

[44]  I. Valverde,et al.  Glucagon-like peptide-1 binding to rat skeletal muscle , 1995, Peptides.

[45]  J. Rodin,et al.  Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. , 1995, Metabolism: clinical and experimental.

[46]  S. Mojsov,et al.  Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.

[47]  I. Valverde,et al.  Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. , 1993, Endocrinology.

[48]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.